This approach leverages thermosensitive liposomes (TSLs) loaded with IGFBPL1 that undergo controlled drug release when exposed to mild hyperthermia (40-45°C) generated by focused ultrasound. The liposomes are formulated with temperature-sensitive phospholipid compositions, particularly dipalmitoylphosphatidylcholine (DPPC) and lysolipids, which undergo phase transitions at specific temperatures, creating membrane permeability changes that enable rapid drug release within 10-20 seconds of heating. Unlike microbubble cavitation that mechanically disrupts the BBB, this mechanism preserves BBB integrity while achieving targeted drug release through precise thermal control. The focused ultrasound operates at higher frequencies (1-3 MHz) optimized for heating rather than cavitation, generating localized temperature elevations through acoustic absorption in brain tissue. IGFBPL1 release kinetics are controlled by the lipid phase transition temperature, allowing for sustained therapeutic concentrations over 2-6 hours.

This approach leverages thermosensitive liposomes (TSLs) loaded with IGFBPL1 that undergo controlled drug release when exposed to mild hyperthermia (40-45°C) generated by focused ultrasound. The liposomes are formulated with temperature-sensitive phospholipid compositions, particularly dipalmitoylphosphatidylcholine (DPPC) and lysolipids, which undergo phase transitions at specific temperatures, creating membrane permeability changes that enable rapid drug release within 10-20 seconds of heating. Unlike microbubble cavitation that mechanically disrupts the BBB, this mechanism preserves BBB integrity while achieving targeted drug release through precise thermal control. The focused ultrasound operates at higher frequencies (1-3 MHz) optimized for heating rather than cavitation, generating localized temperature elevations through acoustic absorption in brain tissue. IGFBPL1 release kinetics are controlled by the lipid phase transition temperature, allowing for sustained therapeutic concentrations over 2-6 hours. The intact IGFBPL1 protein maintains its anti-inflammatory activity, binding to microglial LRP1 receptors and activating downstream PI3K/Akt signaling pathways that promote neuroprotective gene expression including arginase-1 and IL-10. This thermal-mediated approach offers superior spatial precision (sub-millimeter targeting) and eliminates risks associated with BBB disruption, including potential for hemorrhage or edema. The liposomal carriers can be engineered with surface modifications such as transferrin or lactoferrin conjugation to enhance brain uptake through receptor-mediated transcytosis, providing dual targeting mechanisms for neuroinflammatory conditions including multiple sclerosis, Alzheimer's disease, and traumatic brain injury.